AusBiotech disappointed as R&D Tax Incentive 1.5% cut returns to Parliament

28 May 2015
2019_biotech_test_vial_discovery_big

Trade group AusBiotech has expressed bitter disappointment at the Australian government's move yesterday to re-introduce legislation to cut the Research and Development Tax Incentive benefit by 1.5%, and urged the Senate to reject the legislation.

The 'Tax and Superannuation Laws Amendment (2015 Measures No 3) Bill 2015', tabled yesterday, includes the 1.5% cut which was originally announced in the May 2014 Federal Budget, but failed to get support in the Senate and the Bill was defeated last year.

The change will permanently impact companies while they are in tax loss, and adversely impact the same small businesses that were singled out for special support in the year's Budget with a 1.5% corporate tax cut, says AusBiotech.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology